Fact checked by Nick Blackmer Zunveyl (benzgalantamine)—a better-tolerated version of the Alzheimer’s drug Razadyne ...

A report from the U.S. FDA's Office of Inspector General is calling into question the thoroughness of the agency's ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

This has demonstrated the potential of palbociclib in treating Alzheimer’s disease,” Chen said. The research shows the drug ...

Older studies estimated a lower risk of dementia. According to new research, the number of people living with the disease in ...

On Monday, the FDA accepted Eisai Co., Ltd. (OTC:ESALY) and Biogen Inc’s (NASDAQ:BIIB) Biologics License Application (BLA) ...

New research suggests that the risk for developing dementia is significantly higher than previously estimated, and the burden ...

The finding has implications for all of us, write Harvard physician-researchers Christopher Worsham and Anupam Jena.

Biogen (BIIB) and Eisai's (ESALF) (ESAIY) announce that U.S. FDA agreed to review their subcutaneous form of Alzheimer's ...

Jan. 8, 2025 — Declining blood levels of two molecules that occur naturally in the body track closely with worsening Alzheimer's disease, particularly in women. Levels were found to drop ...

(Bloomberg) -- Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for Alzheimer’s disease in 2025. Companies including Biogen ...